Tin tức & Cập nhật
Xem bài viết Dược
Xem

Noninvasive UGN-102 therapy delivers durable response in recurrent LG-IR-NMIBC
Patients with recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer (LG-IR-NMIBC) who achieved an initial complete response (CR) to UGN-102 treatment tend to remain event-free 24 months later, according to phase III ENVISION trial.
Noninvasive UGN-102 therapy delivers durable response in recurrent LG-IR-NMIBC
05 Aug 2026
ASCVD affects 1 in 6 adults with β-thalassaemia; etopivat shows promise
Atherosclerotic cardiovascular disease (ASCVD) affects a substantial proportion of adults with β-thalassaemia. It appears to be driven by conventional CV risk factors rather than disease-specific features, according to research presented at EHA2026.
ASCVD affects 1 in 6 adults with β-thalassaemia; etopivat shows promise
04 Aug 2026
Izokibep maintains PsA efficacy at 52 weeks
The novel small-protein IL-17 inhibitor izokibep demonstrates durable efficacy and a favourable safety profile over 52 weeks in patients with active psoriatic arthritis (PsA), with sustained improvements in joint, skin, and quality-of-life outcomes in a phase IIB/III study.






